ORTX - Orchard Therapeutics plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Orchard Therapeutics plc

108 Cannon Street
London EC4N 6EU
United Kingdom
44 20 3384 6700
http://www.orchard-tx.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees180

Key Executives

NameTitlePayExercisedYear Born
Mr. Mark A. RotheraCEO, Pres & DirectorN/AN/A1963
Mr. Frank E. ThomasCFO & Chief Bus. OfficerN/AN/A1970
Ms. Ran ZhengChief Technical OfficerN/AN/AN/A
Prof. Bobby Gaspar Ph.D., M.D.MD, Chief Scientific Officer, Member of Scientific Advisory Board & DirectorN/AN/A1964
Ms. Renee LeckDirector of Investor RelationsN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-201 for mucopolysaccharidosis type MPS-IIIA and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is based in London, the United Kingdom.

Corporate Governance

Orchard Therapeutics plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.